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The brain is vulnerable to hypoglycaemia due to a continuous need of energy substrates to meet its highmetabolic demands. Studies
have shown that severe acute insulin-induced hypoglycaemia results in oxidative stress in the rat brain, when neuroglycopenia
cannot be evaded despite increased levels of cerebral glucose transporters. Compensatory measures in the brain during chronic
insulin-induced hypoglycaemia are less well understood. The present study investigated how the brain of nondiabetic rats copes
with chronic insulin-induced hypoglycaemia for up to eight weeks. Brain level of diﬀerent substrate transporters and redox
homeostasis was evaluated. Hyperinsulinaemia for 8 weeks consistently lowered blood glucose levels by 30–50% (4–6mM versus
7–9mM in controls). The animals had increased food consumption, body weights, and hyperleptinaemia. During infusion,
protein levels of the brain neuronal glucose transporter were decreased, whereas levels of lipid peroxidation products were
unchanged. Discontinued infusion was followed by transient systemic hyperglycaemia and decreased food consumption and
body weight. After 4 weeks, plasma levels of lipid peroxidation products were increased, possibly as a consequence of
hyperglycaemia-induced oxidative stress. The present data suggests that chronic moderate hyperinsulinaemic hypoglycaemia
causes increased body weight and hyperleptinaemia. This is accompanied by decreased neuronal glucose transporter levels,
which may be leptin-induced.
1. Introduction
Acute hypoglycaemia is a common complication in type 1 as
well as in type 2 diabetic patients during intensive insulin
therapy [1–3]. Frequent episodes are likely to weaken the
normal counterregulatory responses and patient awareness
of hypoglycaemia and may thus over time increase the inci-
dence and severity of such episodes [4–6]. Due to the high
metabolic activity of neurons, requiring a continuous supply
of nutrients such as glucose or glucose-derived lactate, the
brain is vulnerable to acute severe hypoglycaemia [7], which
may lead to coma and neuronal necrosis [7–10].
Several studies have investigated the eﬀect of acute
insulin-induced hypoglycaemia in rats with blood glucose
levels of 2-3mmol/l or even below 2mmol/l, that is, levels
that may induce isoelectric EEG and coma [7, 8, 11–14].
Acute severe insulin-induced hypoglycaemia (<2.3mM, ≤5
days) causes an adaptive increase in mRNA and protein
levels of neuronal and blood-brain barrier (BBB) glucose
transporters most likely to ensure adequate glucose supply
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to neurons [7, 11, 12, 15]. Indeed, insuﬃcient cerebral glu-
cose inﬂux during hypoglycaemia has detrimental conse-
quences leading to oxidative stress and regional neuronal
death [7, 9, 16–18]. Thus, increased lipid oxidation can
occur in the brain of rats and mice already after a sin-
gle episode of insulin-induced hypoglycaemia if the
hypoglycaemia is severe enough [17–19].
In contrast, eﬀects of chronic (≥2 weeks) insulin-induced
hypoglycaemia on cerebral glucose transporter levels or
extent of oxidative damage to brain lipids have only been
sparingly investigated [7]. The brain may be better equipped
for prolonged but moderate lowering of blood glucose levels
in contrast to acute or recurrent severe hypoglycaemia,
which usually represents iatrogenic low blood glucose levels
far below fasting levels, approaching a coma-inducing hypo-
glycaemic level. It is not clear if the brain is able to adapt to
restricted glucose availability during extended periods and
prevent neuroglycopenia or if cerebral damage due to oxida-
tion of brain lipids will develop over time. Oxidative damage
to brain lipids seems to be mediated through a reduction
in antioxidant enzymes in the mitochondria combined
with an increased production of reactive oxygen species in
neurons [7, 16–20]. Furthermore, hypoglycaemia-induced
oxidative damage to brain lipids seems to precede neuro-
nal death [7, 19], suggesting that increased lipid peroxida-
tion might be an early marker of hypoglycaemia-induced
cerebral damage.
This prompted us to investigate how the brain from nor-
moglycaemic healthy rats copes with long-term, persistent
hyperinsulinaemic hypoglycaemia at a level corresponding
to that achieved by fasting and using brain substrate trans-
porter and lipid peroxidation product levels as indicators
of adaptation and early damage, respectively. This should
increase knowledge on regulation of brain transporters and
increase the understanding of brain and body response to
metabolic disturbances, which in this case consists of an
induced paradoxical state of opposing metabolic signals of
nutrient surplus (hyperinsulinaemia) and nutrient scarcity
(hypoglycaemia), which would not otherwise occur together.
Additionally, a period of recovery following eight weeks of
hyperinsulinaemic hypoglycaemia was included to investi-
gate reversibility of any changes induced.
2. Materials and Methods
2.1. Animals. Male and female Sprague-Dawley (Crl:CD
(SD)) rats (n = 76/sex, 6-7 weeks old) were supplied by
Charles River Limited (UK). The animals were acclimated
to local environmental conditions (19–23°C, 40–70% humid-
ity, 12 h light-dark cycle, lights on at 6:00 am) for at least ﬁve
days and housed up to ﬁve animals/cage in solid-bottom
polycarbonate cages with a stainless steel mesh lid and saw-
dust litter. They were oﬀered a commercial diet (Rat and
Mouse No. 1 Maintenance Diet, Special Diet Services, Essex,
UK) and water ad libitum. The animals were randomised
into four main groups stratiﬁed for body weight and sex
(Table 1). To allow for infusion (see Study Design), the
animals received surgical implantation of a vascular cathe-
ter inserted into the caudal vena cava through the right
femoral vein as previously described [21]. Postsurgery
animals were single-housed and allowed at least seven days
of recovery before start of insulin infusion. Body weight
was monitored daily for at least three days postsurgery or
until the animals regained their presurgery body weights;
hereafter, body weight and food consumption were moni-
tored twice weekly. The animals were inspected visually for
clinical signs of hypoglycaemia and function of the infusing
system at least four times daily during the infusion phase.
All procedures involving live animals were performed
under the Project Licence authorized by the United Kingdom
Secretary of State and according to EC Commission Directive
2004/10, OECD Principles and Good Laboratory Practice,
and The Good Laboratory Practice (Codiﬁcation Amend-
ments Etc.) Regulations 2004 [22–24] as well as Envigo and
Novo Nordisk A/S company policies on the care and use of
laboratory animals.
2.2. Study Design. At infusion start (Day 1), male and female
rats were approximately 8-9 weeks old, and they received
either 28 (until Day 29) or 56 (until Day 57) full days of
Table 1: Overview of study design (a) and doses (b).
(a)
Day 1 Day 29 Day 57 Day R2 Day R29
Sacriﬁce Sacriﬁce Sacriﬁce Sacriﬁce
n = 9/sex/group n = 10/sex/group n = 9/sex/group n = 10/sex/group
Infusion Infusion-free recovery
(b)
Group n HI dose during infusion (nmol/kg/day)
CTRL-M/CTRL-F 38/38 0/0
HI-M/HI-F 38/38 72>60∗/54>48∗
HI: human insulin, CTRL-M: control group males, CTRL-F: control group females, HI-M: HI-infused males, HI-F: HI-infused females. ∗Doses were lowered
day 12 or day 19 due to clinical signs of severe hypoglycaemia andmortalities related to hypoglycaemia. As the animals started infusion in the two cohorts, doses
were lowered on two diﬀerent dosing days.
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human insulin (HI), group HI-M and HI-F, or vehicle, group
CTRL-M and CTRL-F, infusion or 56 full days of infusion
(M:males, F: females). This was followed by either one (termi-
natedonDay2)or28(terminatedonDay29afterinfusion-stop)
full infusion-free days before termination. Doses are listed in
Table 1. The aim was to approach the maximum tolerable
dose of HI-infusion for up to 8 weeks in order to achieve a
persistent and maximal pharmacodynamic eﬀect. Conse-
quently, the animals were closely monitored for clinical signs
of hypoglycaemia, and doses were lowered, if the maximum
tolerable dose was considered to be exceeded. Doses were
chosen based on results from a previous 4-week HI-infusion
study [21]. Females received lower doses than males as they
are known to possess higher insulin sensitivity [25–27]. Flow
rates (1.4ml/kg/hour) were adjusted on a weekly basis
according to individual body weight gain to keep doses
constant in nmol/kg/day over the infusion period, whereas
insulin concentration was kept constant for each dose level.
Infusion formulation was renewed on a daily basis.
Animals with signs of hypoglycaemia (that is, tremor,
underactivity/lethargy, piloerection, reduced body tempera-
ture, hunched posture, ﬂat posture/collapsed, irregular
breathing, and convulsions associated with low blood glucose
values) were treated with glucose (p.o. or i.v.) immediately
after recognition of clinical signs of hypoglycaemia. However,
based on severe hypoglycaemic events leading to termination
of the animals for welfare issues in three animals (two males
and one female) within the ﬁrst two weeks of the study, the
dose levels were lowered in the male and female HI-infused
groups (Table 1).
The animals were terminated after four or eight weeks of
infusion on Day 29 (n = 9/group) or Day 57 (n = 10/group),
respectively (Table 1). Infusion was ongoing until termina-
tion. After the end of infusion on Day 57, nineteen animals
per group were kept on study and subjected to one
(n = 9/group) or 28 (n = 10/group) full days of infusion-free
recovery period, that is, to days 2 and 29 of recovery (Day
R2 and R29). At termination, all the animals were subjected
to a detailed necropsy. Right cerebrum hemisphere with right
half of the cerebellum and left cerebrum hemisphere with left
half of the cerebellum, respectively, were freeze-clamped in
liquid nitrogen and stored at approximately −80°C. From
the animals terminated on Day 29, 57, and R29, the right half
was used for western blot analysis and the left half for quan-
tiﬁcation of brain tissue lipid oxidation.
2.3. Blood Sampling. Two types of sampling for blood glucose
measurements were included: plasma (sublingual vein under
isoﬂurane anaesthesia) for glucose proﬁling and single time-
point measurements on selected days and whole blood (tail
vein, no anaesthesia) to allow for continuous single time-
point assessment of all the animals, which is not possible with
the plasma measurements, as they require a larger blood
volume as well as anaesthesia of the animal at each sampling.
Plasma was sampled for glucose proﬁling to monitor the
decrease in blood glucose levels following the start of HI-
infusion in the morning of Day 1 and on Day 25 and Day
53 (at 0.25, 0.5, 6, 12, or 24h, relating to the start of infusion
at 0 h on day 1); time points were determined based on the
approximate half-life of HI in the rat of approximately
0.25 h [28], as well as on results from a previous study using
the same animal model [21], and to conﬁrm a persistent 24 h
decrease as would be expected from continuous infusion. As
this was the main purpose, only 2 animals/sex/group were
sampled at each time point, to minimise stress (induced by
handling and/or sampling) in the animals. Furthermore, the
animals were sampled on the ﬁrst day of the infusion-free
recovery period (Day R1), at 0.25, 0.5, 6, 12, or 24 h after
infusion-stop. In addition, blood samples for plasma glucose
quantiﬁcation were obtained at a single time point from all
the animals on day 8 and before termination of the animals
on Day 29, Day R2, and Day R29. Plasma glucose level
was quantiﬁed as described previously [21]. On Day 1 and
53, blood was drawn also for plasma HI quantiﬁcation
at the same time points as for plasma glucose proﬁling
measurements. Additional plasma samples for analysis of
biomarkers of lipid oxidation were obtained at termina-
tion. Whole blood glucose levels were monitored with a
snap blood glucose monitoring device (Accu-Chek Aviva,
Cat/Type 05911974002, Roche Diagnostics, Burgess Hill,
West Sussex, UK); all the animals were sampled twice weekly
during the infusion period and once weekly during the
infusion-free recovery period. The frequency of sampling
was reduced if there was a scheduled plasma glucose proﬁle
within that week.
2.4. Insulin Formulations and Infusion System. The infusates
used were recombinant HI stock solution formulated in a
phosphate buﬀered vehicle (600 nmol/ml) and buﬀered
vehicle (Novo Nordisk A/S, Maaloev, Denmark), diluted in
dilution medium. Composition of buﬀered HI stock formula-
tion, buﬀered vehicle, and dilution medium was as described
previously [21]. For the infusion, external syringe infusion
pumps and a vascular access harness connected to a tether
kit were used as described previously [21].
2.5. Plasma HI Levels and Toxicokinetic Analysis. HI concen-
tration was quantiﬁed in plasma by the use of a luminescent
oxygen channelling immunoassay as described previously [21].
The lower limit of quantiﬁcation (LLOQ) of the assay was
25pmol/l. Samples were analysed in duplicate; results were
reported as the mean of the two replicates.
For toxicokinetic analysis, composite mean proﬁles of
plasma concentration versus time data from male and female
rats were generated and subsequently treated as full proﬁles.
The steady state concentrations (Css) were calculated based
on noncompartmental analysis. For a continuous i.v. infusion
of HI, the plasma concentration of HI is per deﬁnition con-
stant at all time points. For Day 1, the concentrations from
6 to 24h represent Css, as steady state is theoretically obtained
after 5–7 half-lives (half-life of HI in rats is approximately
14min [28]). Hence, on Day 1 from 6 to 24h and for all time
points on day 53, mean plasma concentrations for each ani-
mal and for each HI-infused group were calculated to yield
individual and group mean Css. Toxicokinetic calculations
were performed in Phoenix™WinNonlin® version 6.2, build
6.2.0.495 (Pharsight®, St. Louis, Missouri, USA).
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2.6. Protein Extraction and Western Blotting. Approximately
35–45mg of frozen pulverized brain tissue (right hemisphere
with right half of the cerebellum) was homogenized in 250μl
cold radio-immunoprecipitation assay (RIPA) buﬀer (50 nM
Tris [pH 8.0], 150mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate) containing
protease inhibitor cocktail diluted 1:100 (Sigma-Aldrich,
St. Louis, MO, USA). The homogenate was centrifuged
(10min, 15300×g, 4°C) and the supernatant transferred to
fresh Eppendorf tubes and frozen immediately at −20°C.
Protein concentrations were determined in triplicate by a
bicinchoninic acid assay (BCA Protein Assay Kit, Merck
Life Science A/S, Hellerup, Denmark) at 562nm by spectro-
photometry (Spectra Max Plus 384 UV/VIS plate reader,
Molecular Devices Inc., Sunnyvale, CA, USA) according to
the manufacturer’s protocol. Puriﬁed protein (25μg) diluted
with nuclease-free water and sample buﬀer (4x Laemmli
SampleBuﬀer, Bio-RadLaboratories,Copenhagen,Denmark)
was heated at 70°C for 10min, loaded on precast polyacryl-
amide gels (Any KD Criterion TGX gel, Bio-Rad Laborato-
ries, Copenhagen, Denmark), and run in duplicate at
200 volts in 1x Tris/glycine/SDS running buﬀer (25mM
Tris, 192mM glycine, 0.1% SDS, pH 8.3) (Bio-Rad Lab-
oratories, Copenhagen, Denmark). A protein size standard
(MagicMark™ XP, Life Technologies Europe BV, Naerum,
Denmark) and an internal calibrator were included on each
gel, and positive and negative controls were included in each
run. Gel to membrane transfer of protein was performed in a
Trans-Blot® Turbo™ Transfer System (Bio-Rad Laboratories,
Copenhagen, Denmark) using a LF PVDF Transfer Kit
(Bio-Rad Laboratories, Copenhagen, Denmark) according
to the manufacturer’s protocol prior to 1 hblocking in 2%
blocking solution containing Amersham™ ECL Advance™
Blocking Reagent (Fisher Scientiﬁc, Roskilde, Denmark) in
PBS-T wash buﬀer (1x PBS and 0.1% Tween 20). Following
blocking, membranes were incubated with primary antibody
(Table 2) in the blocking solution at 4°C overnight, washed in
PBS-T wash buﬀer, and incubated with goat anti-rabbit
secondary antibody (#170-6515, Bio-Rad Laboratories,
Copenhagen, Denmark) in the blocking solution for 1 h at
room temperature, followed by washing in PBS-T wash
buﬀer. Imaging was achieved by enhanced chemilumines-
cence (WesternBright Quantum Chemiluminescent HRP
Substrate, Advansta Corporation, Menlo Park, CA, USA) in
an Odyssey Fc Imager (LI-COR® Biosciences UK Ltd.,
Cambridge, UK). Optical density of protein bands was deter-
mined using the Image Studio™ Software (LI-COR Bio-
sciences UK Ltd., Cambridge, UK). Signal density was
normalised to the corresponding actin signal and to the
internal calibrator; results were reported as a mean value
of the two duplicates. Speciﬁcity of the primary antibodies
was conﬁrmed by a preabsorption test with the corresponding
blocking peptides (Table 2).
2.7. Levels of Lipid Oxidation Products. Oxidative damage
to brain lipids was assessed by measuring levels of malon-
dialdehyde (MDA) in brain tissue and plasma as described
elsewhere [29] and plasma levels of 8-F2-isoprostanes (8-ISO)
as described by the assay kit manufacturer (cat. number
516351, Cayman Chemical Company, Ann Arbor, MI, USA).
This was measured in homogenates of left hemisphere
with left half of the cerebellum.
2.8. Plasma Levels of Leptin. Plasma levels of leptin were mea-
sured using a commercially available luminescent oxygen
channelling assay for detection of mouse leptin (cat. number
AL521 C/F, Perkin Elmer Inc., Waltham, MA, USA) as
described by the assay kit manufacturer, except for the
following modiﬁcations: rat plasma was treated with acti-
vated decolorizing carbon and was then used to prepare stan-
dards and controls for the assay. It was furthermore used to
dilute samples (4x). The lower limit of quantiﬁcation (LLOQ)
of the assay was 1.2 ng/ml. Sample volume used was 5μl, and
they were analysed as single-determinations.
2.9. Statistical Analysis.Data for body weight, food consump-
tion, and whole blood glucose levels was compared by multi-
ple t-tests using the Holm-Sidak method; each time point was
analysed separately without assuming a consistent SD. For
body weight and food consumption, each sex was analysed
separately. All other data was evaluated at each time point
separately using a two-way ANOVA testing for eﬀect of
HI-dosing and sex. In case of interaction, a post hoc Sidak’s
test for eﬀect of HI-dosing and for eﬀect of sex, respectively,
was performed. Second, an additional analysis was performed
for parametersmeasured at bothDay 29 andDay 57 of infusion,
if there was no interaction or eﬀects of sex andHI-infusion. The
CTRL-M and CTRL-F as well as HI-M and HI-F groups,
Table 2: Antibodies used for western blotting.
Transporter
Primary antibody
(cat. number)
Company
Working
dilution
Size of band(s)
detected (kDa)
Blocking peptide
(cat. number)
Host species of
primary antibody
Secondary
antibody dilutiond
GLUT1 07-1401 MLSa 1:8000 43 N/A Rabbit 1:3000
GLUT3 ab15311 Abcamb 1:400 38, 45, and 50 N/A Rabbit 1:1500
SGLT1 ab14686 Abcam 1:1000 30, (42) ab190911 Rabbit 1:2000
MCT1 AB3540P MLSa 1:5000 40 N/A Rabbit 1:4000
Actin Ab1801 Abcam 1:1000 10, 25, 30, and 42c ab13771 Rabbit 1:2000
N/A, not applicable as the corresponding blocking peptide was not commercially available; instead, one was custom synthesized (CASLO ApS, Kgs. Lyngby,
Denmark) according to the peptide sequence supplied by the manufacturer of the primary antibody. All custom-synthesized blocking peptides were
supplied at >95% purity. aMerck Life Science A/S, Hellerup, Denmark. bAbcam plc., Cambridge, UK. cTriple band. dThe same secondary goat anti-rabbit
(#170-6515, Bio-Rad Laboratories, Copenhagen, Denmark) was used for all primary antibodies.
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respectively, were pooled together for both time points, and a
two-way ANOVA was performed on this data (that is, HI-M
+F versus CTRL-M+F) from both time points to test for eﬀect
of duration of infusion and for an overall eﬀect of HI-dosing
regardless of duration of infusion. In case the ﬁrst analysis on
each time point separately revealed an eﬀect of sex, this second
analysis was performed for each sex separately.
3. Results
3.1. Animals. After surgery, the animals generally behaved
normally without any signs of discomfort or stress resulting
from the catheter and/or harness. Out of the 152 animals in
total, 34 were terminated or died prematurely during the study.
Of these, 12 were related to hypoglycaemia, 15 to problems
with the infusion system (e.g., catheter becoming disconnected
or regressing under the skin), 5 due to poor clinical condition
or limb problems, and 2 (controls) for unknown reasons.
Mean body weight was signiﬁcantly increased by appro-
ximately 10% after eight weeks of HI-infusion in males and
females compared to that of the control groups (Figure 1(a);
p < 0 001 in HI-M and p < 0 01 in HI-F versus CTRL).
Following discontinuation of infusion, an initial decrease in
body weight was observed in the male and female HI-infused
R8 R11 R15 R18 R22 R25 R29‒7 1 4 7 10 14 18 22 25 29 32 36 39 43 46 50 53 57/R1 R4
0
100
200
300
400
500
600
700
Bo
dy
 w
ei
gh
t (
g)
Study day
CTRL-M
HI-M
CTRL-F
HI-F
⁎
⁎⁎
⁎⁎⁎
⁎⁎
⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎ ⁎⁎⁎ ⁎⁎⁎ ⁎⁎
⁎⁎
⁎⁎
⁎⁎
⁎⁎
⁎⁎ ⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
(a)
‒4 1 4 8 11 15 18 22 25 29 32 36 39 43 46 50 53 57 R4 R8 R11 R15 R18 R22 R25 R29
10
15
20
25
30
35
40
45
50
Fo
od
 co
ns
um
pt
io
n 
(g
/a
ni
m
al
/d
ay
) 
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎
⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎
⁎
⁎
⁎
⁎
⁎
Study day
CTRL-M
HI-M
CTRL-F
HI-F
(b)
Figure 1: (a) Body weight, group mean+ SD. (b) Food consumption, group mean + SD. Grey areas indicate infusion period. Days −7 to 29:
n = 32− 38/group per time point, days 32–57: n = 20− 28/group per time point (except for days 53 and 57 for group HI-M, where
n = 15− 17/time point), and days R4–R29: n = 5− 10/group per time point. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 versus controls.
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groups, rendering body weights similar to CTRL group body
weights for the remainder of the study. Food consumption
was generally signiﬁcantly increased during HI-infusion
(Figure 1(b)), with the eﬀect being most pronounced during
the ﬁrst three weeks of HI-infusion (≤26% increase in the
HI-M and ≤20% in the HI-F group compared to that in the
controls). Discontinuation of infusion was followed by a
signiﬁcant decrease in food consumption in groups HI-M
and HI-F by approximately 40% compared to that in the
controls during the ﬁrst four days of the infusion-free
recovery period (Figure 1(b); p < 0 001). Food consumption
was still decreased by Day R8 by approximately 10% in
group HI-M (p = 0 16) and 20% in group HI-F (p < 0 01).
There was no signiﬁcant diﬀerence in food consumption from
Day R11 and onwards.
3.2. Plasma HI Levels and Toxicokinetic Analysis. All the
sampled animals from the HI-F and HI-M groups were
systemically exposed to HI, and in all plasma samples from
the animals in the control groups, HI concentrations were
below the LLOQ (25 pmol/L) (data not shown). On Day 1,
there was a trend for increasing plasma HI concentrations
from 0.5 hours after infusion start. The mean group steady
state HI concentrations, Css, ranged between 1600 and
3100 pmol/l (Table 3). Despite diﬀerent dose levels of HI,
there was no statistical diﬀerence in exposure between
mean Css on Day 1 versus Day 53 or between HI-infused
males and females.
3.3. Blood Glucose Levels
3.3.1. Plasma Glucose Levels. On Day 1, plasma glucose con-
centrations in the HI-infused males and females groups
began to decline steadily from 0.5 h after infusion start, and
at the 24 h time point day 1, the values were approximately
60% of the control values (Figure 2(a)). On Day 25 and 53,
plasma glucose concentrations were generally lower in the
HI-infused groups compared to those in the controls except
for two of the time points on Day 25 (6 and 12 h) and Day
53 at 6 h, where levels were similar to those in the controls
(Figures 2(b) and 2(c)). Also, for the single time-point mea-
surements on Day 8 and 29 (Table 4), plasma glucose
levels in the HI-infused groups were signiﬁcantly lowered
to approximately 50–70% of the control values (p < 0 001),
with no diﬀerence between males and females. From 0.5
to 6 h after termination of infusion on Day R1, plasma
glucose levels in groups HI-M and HI-F were generally
higher than those in the controls (Figure 2(d)). On Day R2
(single time-point measurements), group HI-M had signiﬁ-
cantly higher plasma glucose levels than groups CTRL-M
(+114%) and HI-F (Table 4, p < 0 01 and p < 0 05, resp.),
whereas on Day R29, plasma levels of MDA on groups.
3.3.2. Whole Blood Glucose Levels. During the infusion
period, whole blood glucose concentrations were generally
signiﬁcantly lowered to approximately 4-5mM in the HI-
infused animals compared with stable concentrations of
about 7mM in the control groups (Figure 2(e)), generally with
no diﬀerence between sexes. After termination of infusion,
mean whole blood glucose level in the HI-M group tended to
be higher than that in the control animals on Day R5 and
Day R12 (Figure 2(e)); however, this was not signiﬁcant
(p = 0 055 and p = 0 051, resp.). In the remaining infusion-
free period, there was no signiﬁcant diﬀerence in whole blood
glucose levels between the groups, except for the HI-F group
having slightly increased levels on Day R26 (p < 0 05).
3.4. Protein Levels of Substrate Transporters in Brain Tissue
3.4.1. Eﬀects during Infusion. Only levels of the 45 kDa
(astrocytic) isotype of GLUT1 were detected and quanti-
ﬁed. Mean levels of GLUT1 protein in brain tissue homog-
enates were similar for the HI-infused and control groups
after 4 weeks (Day 29, p = 0 1375) and 8 weeks (Day 57,
p = 0 8924) of infusion (Figure 3(a)). On Day 57, there was
an eﬀect of sex with higher GLUT1 protein levels in females
(p = 0 0172). Therefore, each sex was tested separately for
an overall eﬀect of HI-infusion, revealing no signiﬁcant eﬀect
in males or females (p = 0 1655 and p = 0 4125).
There was no eﬀect of HI-infusion on GLUT3 levels after
4 weeks or 8 weeks (p = 0 1361 and p = 0 1140, resp.)
(Figure 3(b)). As there was no eﬀect of sex on each time point
(p = 0 4493 and p = 0 1309, resp.), males and females were
pooled within each group to test for an overall eﬀect of
HI-infusion regardless of duration. This revealed an overall
signiﬁcant decrease (p = 0 0389) of GLUT3 levels in the
brains from the HI-infused animals (Figure 3(c)).
SGLT1 protein levels were not aﬀected by HI-infusion for
4 or 8 weeks (p = 0 4694 and p = 0 0703, resp.), although
approaching a signiﬁcant decrease after 8 weeks, and were
not diﬀerent between males and females (p = 0 7508 and
p = 0 7486) (Figure 3(d)). Testing for an overall eﬀect of
HI-infusion revealed no signiﬁcant diﬀerences (p = 0 1481).
MCT1 protein levels were not aﬀected by sex (p = 0 0849)
or HI-infusion (p = 0 6219) after 4 weeks; however, after
8 weeks of infusion, there was interaction between eﬀect of
HI-infusion and sex (p = 0 0433) (Figure 3(e)). Post hoc test-
ing for eﬀect of HI-dosing in each sex separately and eﬀect of
sex in each dose-group separately revealed no signiﬁcant
changes (p values all above 0.05). Representative pictures of
the western blots are included in Figure 3(f).
3.4.2. Eﬀects after Infusion. There were no eﬀects of HI-
dosing or sex on protein levels of any of the transporters after
4 weeks of infusion-free recovery period (data not shown).
3.5. Levels of Lipid Peroxidation Products. Levels of MDA
in brain tissue were unaﬀected by HI-infusion or sex (all
p values> 0.05) at any of the time points and also in the
second test for overall eﬀect of HI-infusion (p = 0 5435)
(Figure 4). For plasma levels of MDA on Day 57, a two-way
ANOVA testing for eﬀect of HI-dosing and sex showed no
interaction (p = 0 0818), no eﬀect of dosing (p = 0 3262),
Table 3: Estimated group mean Css of HI in plasma (pmol/l).
Group n Day 1a (Range)b n Day 53 (Range)b
HI-M 6 1780 (502–3050) 8 1780 (222–7870)
HI-F 6 3120 (135–14900) 6 1590 (180–4360)
a6–24 h. bOf individual means.
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Figure 2: Blood glucose levels. Plasma proﬁle Day 1 (a), Day 25 (b), Day 53 (c), and Day R1 (d). Individual (symbols) and mean (lines) values,
n = 1− 2/time point. Infusion start was deﬁned as time point zero on day 1. Time point zero on day R1 corresponds to the time point when
infusion was stopped. (e) Whole blood mean values + SD. Grey area indicates infusion period. During infusion: days 2–23: n = 28− 38/group
per time point, days 26–51: n = 22− 28/group per time point, and day 54: n = 12− 17/group per time point. During infusion-free period
(recovery): n = 5− 10/group per time point. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 for HI-M versus CTRL-M; #p < 0 05, ##p < 0 01,
and ###p < 0 001 for HI-F versus CTRL-F. Levels in the HI-M and HI-F groups were only signiﬁcantly diﬀerent on two time points: day
5 (p < 0 05) and day R12 (p < 0 05).
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but an eﬀect of sex (p = 0 003), with higher levels in females.
Day R29: n = 5− 10, a two-way ANOVA testing for eﬀect of
HI-dosing and sex showed no interaction (p = 0 0639), no
eﬀect of dosing (p = 0 1704), but an eﬀect of sex (p = 0 0003),
with higher levels in females (Figure 5(a)). For plasma 8-ISO
levels on Day 57, there was interaction (p = 0 0129) between
eﬀect of HI-infusion and sex. The post hoc analysis revealed
an eﬀect of HI-infusion in males (Figure 5(b), p = 0 0316),
with no eﬀect in females (p = 0 4830) and an eﬀect of
sex within the CTRL group, with higher levels in females
(p = 0 0297). On Day R29, 8-ISO levels were signiﬁcantly
increased in the animals previously infused with HI
compared to those in the control animals (Figure 5(b),
p < 0 001).
3.6. Plasma Leptin Levels. Results are shown in Figure 6.
HI-infusion caused signiﬁcant increase of leptin levels
after both 28 and 56 days of infusion (p < 0 0001 on both
days), which was back to normal after 28 days of infusion-
free recovery (p = 0 6726). At all the three time points
measured, leptin levels were signiﬁcantly higher in males
compared to those in females (p = 0 0325, p < 0 0001, and
p = 0 0182, resp.).
4. Discussion
Interestingly, the present study shows that chronic hyperin-
sulinaemic hypoglycaemia in healthy rats leads to hyperlepti-
naemia and a decrease in levels of the neuronal glucose
transporter GLUT3 in the brain. Despite the hypoglycaemia
and this decrease in glucose transporter levels, no general
increase in lipid oxidation production was seen in the brain.
Discontinuation of insulin infusion resulted in transient
hyperglycaemia and signiﬁcantly increased plasma levels of
lipid oxidation products four weeks later, suggesting systemic
lipid oxidation. HI-infusion induced continuous moderate
lowering of blood glucose levels to approximately 50–70%
of the controls (mean levels of 4–6mM versus 7–9mM
in the controls), which is more pronounced than the
reduction seen after short-term fasting in rats (70–80%
of controls) [30–32]. More severe hypoglycaemia (such as
levels < 2 5mM, that is, <40% of the controls) leading to
clinical signs requiring glucose intervention and euthanasia
was observed in several animals within the ﬁrst few weeks
of the study, and consequently, HI doses were lowered. HI-
infusion resulted in increased food consumption and
increased bodyweights, a well-known phenomenon of insulin
dosing [21, 33–35]. The increase in food consumption seemed
most pronounced during the ﬁrst three weeks of HI-infusion;
hereafter, the eﬀect on food consumption attenuated over
time. This could be due to a decrease in the counterregulation
to hypoglycaemia and hypoglycaemia unawareness, that is,
the animals become less responsive to the hypoglycaemia
[5], which also explains why plasma glucose levels were lower
on Day 29 compared to those on Day 8, despite the dose
reduction after approximately two weeks of infusion. HI-
infusion was furthermore accompanied by increased levels
of circulating leptin by approximately 150–180% in males
and 230–400% in females. This hyperleptinaemia was most
likely caused by the increased body weights induced by the
hyperphagia and hyperinsulinaemia, as circulating levels
of leptin are correlated with body fat mass [36].
Relative protein levels of brain glucose transporters
GLUT1 and GLUT3 were investigated as they represent the
main glucose transporters responsible for the basal glucose
transport into astrocytes and neurons, respectively [37].
The neuronal glucose transporter, SGLT1, was also included,
as it has very high aﬃnity for glucose, and might therefore
play an important role during prolonged periods of persistent
hypoglycaemia [7, 38, 39]. Brain tissue levels of the astrocytic
glucose transporter GLUT1 were unchanged by insulin-
induced hypoglycaemia, in line with other studies with hypo-
glycaemia of shorter duration (8–12 days) [14, 37]. However,
an overall decrease of brain GLUT3 levels was seen in the HI-
infused groups versus the controls (decreased by 8–12% in
HI-F and 17-18% in HI-M versus the respective control
groups). Based on ﬁndings in previous studies by others
showing that acute hypoglycaemia of 4–7 days causes
increased GLUT3 expression, and unchanged GLUT3 levels
after a more long-term hypoglycaemic state (8–12 days)
[11, 13, 37], any change to GLUT3 levels was expected to
be an increase to compensate for the low blood glucose levels.
The decrease in cerebral GLUT3 protein levels in the animals
in the present study concomitant with high levels of
circulating insulin and leptin is in agreement with results
from a recent paper showing that neonatal overnutrition in
mice causes increased adult body weight, hyperleptinaemia,
hyperinsulinaemia, and decreased GLUT3 levels in the hypo-
thalamus [40]. This was further supported by an additional
in vivo study, where chronic intracerebroventricular leptin
treatment in mice also induced a decrease in hypothalamic
GLUT3 levels, with no change to GLUT1 levels [40]. Simi-
larly, others have recently shown that, in diet-induced obese
rats with increased plasma levels of insulin and leptin,
GLUT3 mRNA levels are decreased in the olfactory mucosa,
with no change in GLUT1 mRNA level, compared to those in
lean controls [41]. This suggests that leptin levels can regulate
brain GLUT3 levels and that they are inversely correlated
Table 4: Single time-point plasma glucose level (mM), mean± SD.
Group n Day 8a (diﬀerence from control) n Day 29 (diﬀerence from control) n Day R2 (diﬀerence from control) n Day R29b
CTRL-M 36 9.20± 1.06 7 8.57± 0.317 7 7.52± 0.652 10 8.47± 0.75
HI-M 35 6.24± 3.19∗∗∗ (−32%) 8 4.30± 1.883∗∗∗ (−50%) 6 16.10± 7.855∗∗ (+114%) 5 9.83± 1.74
CTRL-F 37 9.05± 0.82 8 9.01± 0.700 6 8.19± 1.003 9 8.42± 0.62
HI-F 37 6.15± 2.74∗∗∗ (−32%) 8 4.84± 1.394∗∗∗ (−46%) 6 9.55± 1.401# 9 8.75± 1.04
a6 h time point. b0.25 h time point. ∗∗p < 0 01 and ∗∗∗p < 0 001 versus control; #p < 0 05 versus HI-M.
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with hyperleptinaemia causing a decrease in GLUT3 levels.
This is supported by in vitro studies as well. A fetal rat
hypothalamic neuronal cell line has decreased GLUT3
levels after incubation with leptin [40], and a study with
a human neuronal cell line suggests that both insulin and
leptin decrease neuronal GLUT3 protein level independently
of each other [42]. This downregulation is also in line with
the fact that high plasma insulin and leptin levels are usually
29 57
0.0
0.5
1.0
1.5
2.0
O
D
 G
LU
T1
/a
ct
in
 (A
U
)
#
CTRL-M
HI-M
CTRL-F
HI-F
(a)
29 57
0.0
0.4
0.8
1.2
1.6
O
D
 G
LU
T3
/a
ct
in
 (A
U
)
CTRL-M
HI-M
CTRL-F
HI-F
(b)
29 57 29 57
0.0
0.4
0.8
1.2
1.6
O
D
 G
LU
T3
/a
ct
in
 (A
U
)
⁎
HI
CTRL
(c)
29 57
0.0
0.1
0.2
0.3
0.4
O
D
 S
G
LT
1/
ac
tin
 (A
U
)
CTRL-M
HI-M
CTRL-F
HI-F
(d)
29 57
0.0
0.2
0.4
0.6
0.8
O
D
 M
CT
1/
ac
tin
 (A
U
)
CTRL-M
HI-M
CTRL-F
HI-F
(e)
GLUT1 GLUT3
SGLT1 MCT1
43 kDa
30 kDa
50 kDa
45 kDa
38 kDa
40 kDa
(f)
Figure 3: Relative protein levels of substrate transporters at the two diﬀerent time points during infusion. Mean + SD. (a) GLUT1, each day
depicted separately, (b) GLUT3, each day depicted separately, (c) GLUT3, overall eﬀect of HI-dosing, sex pooled. (d) SGLT1 and (e) MCT1,
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present concomitant with hyperglycaemia and high fat
mass, respectively, that is, during periods of excess supply
of nutrients [36, 43]. Reversely, naturally occurring hypogly-
caemia induced by fasting is typically accompanied by a
decrease in plasma insulin and leptin levels and increased
neuronal GLUT3 levels, presumably to compensate for
restricted supply of glucose from peripheral circulation
[40]. Therefore, the hyperinsulinaemia and hyperleptinae-
mia may act in concert to decrease brain GLUT3 levels
in the present study, superseding the hypoglycaemic signal
to increase or maintain levels.
Total protein levels of the other neuronal glucose trans-
porter, SGLT1, measured in brain tissue were unaltered by
HI-infusion for up to 8 weeks. Not much is known about
the regulation of SGLT1 levels in the brain, and since this
transporter is mainly located intracellularly [38, 44–46], it
may potentially serve as a reserve pool ready for recruiting
to the plasma membrane when needed. This is supported
by in vitro studies showing increased plasma membrane
SGLT1 levels in glucose-deprived epithelial cells [47, 48]
and an in vivo study reporting an increase in SGLT1-
speciﬁc glucose uptake in the rat brain, when an epileptic sei-
zure was induced as a model for metabolic changes in the
brain [38]. This was hypothesised to be due to increased
translation of SGLT1 and/or by translocation of SGLT1 pro-
tein from an intracellular location to the plasma membrane
[38]. Additionally, regulation of SGLT1-mediated glucose
transport through changes in aﬃnity has also been shown
in vitro [49, 50]. These results collectively suggest that chronic
insulin-induced hypoglycaemia would cause translocation
and/or upregulation of SGLT1 levels. However, in the present
study, there was a tendency for a decline in SGLT1 levels
(6-7% in HI-F and 17–32% in HI-M versus the respective
controls), which approached statistical signiﬁcance after 8
weeks of HI-infusion (2-way ANOVA, p = 0 0703) and
was signiﬁcantly decreased in HI-M after 8 weeks, when
performing a post hoc unpaired t-test on group HI-M
versus CTRL-M (p = 0 0436). SGLT1 levels have been shown
to be decreased by leptin in vitro in rat jejunal mucosa
[51], as well as in vivo in the small intestine of an obese
type 2 diabetic mouse model with hyperleptinaemia [52].
This suggests that, similar to GLUT3, SGLT1 in the brain
may be prone to regulation by leptin with hyperleptinaemia
inducing a downregulation. However, this remains to be
investigated further.
As mentioned above, HI-infusion caused no change in
GLUT1 levels; however, brain GLUT1 levels were signiﬁ-
cantly higher in females compared to those in males on Day
57 (16-17 weeks of age). In agreement with this, higher
GLUT1 mRNA levels have been shown in adipocytes from
females compared to those frommales inmice [53], seemingly
mediated through sex steroids, which is further corroborated
by a study in female estradiol-treated rhesus monkeys [54].
The relevance of this sex diﬀerence in GLUT1 expression is
unknown, and it was not present in 12-13-week-old (day 29)
or 20-21-week-old (day R29) female rats in the present study.
An additional astrocytic transporter, monocarboxylate
transporter MCT1 [55], was included to investigate if chronic
insulin-induced hypoglycaemia would lead to upregulation
of this transporter in order to increase transfer of astrocytic
lactate formed by breakdown of astrocytic glycogen stores
to the extracellular space to make it available as an alternative
energy substrate for the neurons. As for GLUT1, protein
levels of MCT1 were similarly not changed by chronic
hypoglycaemia, which could indicate that MCT1 transporter
levels are adequate to meet the demand for lactate transport
or the transporter’s aﬃnity might be altered towards a
prioritisation of lactate transport.
It is very interesting that, during this restricted supply of
glucose from peripheral circulation, the animals increase
body weights and become hyperleptinaemic. Hyperleptinae-
mia is typically associated with hyperphagic and/or diet-
induced obesity also accompanied by hyperinsulinaemia as
its levels are correlated with fat mass [36, 43], as mentioned
above, and acts centrally to decrease appetite similar to insu-
lin. Despite high circulating levels of insulin and leptin in the
present animal model of hypoglycaemia, the animals have
increased food consumption, presumably driven mainly by
the hypoglycaemia [33]. Normally, hyperinsulinaemia would
only be present with hyperglycaemia, and not much is known
about the central response to chronic hyperinsulinaemic
hypoglycaemia. The hypoglycaemia-induced hyperphagia
despite hyperinsulinaemia has been shown before [21, 34],
indicating that, with regard to control of appetite, the glucose
availability dominates over insulin and leptin signalling, at
least initially in the present model.
Following insulin withdrawal, transient increased blood
glucose levels were accompanied by signiﬁcantly decreased
food consumption and body weight loss. Such transient
hyperglycaemia after cessation of HI-infusion has been
attributed to suppressed endogenous insulin production
[56–58]. However, a study has shown that β-cells quickly
regain insulin production within a few days and is back to
normal within 5 days [35]. This is most likely also what these
changes reﬂect in the present study, with hyperglycaemia
inducing a counterregulatory decrease in food consumption
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until about 8–11 days after cessation of HI-infusion, where
blood glucose levels are back to control levels.
Quantiﬁcation of biomarkers of lipid oxidation in the
brain and plasma was included in the present study as
oxidative stress appears to play an important role in the
pathogenesis of neuronal damage caused by insulin-induced
hypoglycaemia [7, 17–19].MDA and 8-ISO are both products
of oxidative damage to lipids and are consideredbiomarkers of
lipid oxidation [59, 60]. Levels of MDA and ISO-8 were unal-
tered during HI-infusion, suggesting that, in contrast to acute
and recurrent insulin-induced hypoglycaemia [17, 19, 61],
lipid peroxidation is not increased in the brain during chronic
blood glucose lowering. Surprisingly, plasma levels of MDA
were higher in females compared to those in males, despite
an apparent stronger antioxidant defence system in females
compared to that inmale rats [62]. Interestingly, plasma levels
of 8-ISO were signiﬁcantly increased after a 4-week infusion-
free recovery period, which may possibly be due to the tran-
sient hyperglycaemia giving rise to oxidative stress [63, 64];
however, this remains to be clariﬁed.
5. Conclusions
In conclusion, the present study suggests that the brain of
normoglycaemic healthy rats subjected to chronic insulin-
infusion is prone to a downregulation of levels of GLUT3,
the neuronal glucose transporter, despite a lowering of blood
glucose levels by 30–50%. The hyperinsulinaemic hypogly-
caemia was, furthermore, accompanied by increased food
consumption and body weights as well as hyperleptinaemia.
Recent studies by others suggest that the latter may have
induced the decrease in GLUT3 level. Despite hypoglycaemia
and decreased levels of neuronal glucose transporters, there
were no changes to lipid oxidation in brain tissue.
Insulin withdrawal following chronic infusion induced
transient hyperglycaemia—most likely a consequence of
reduced endogenous insulin production—as well as tran-
siently decreased food consumption and body weight and
apparent increased systemic oxidative stress.
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